280 related articles for article (PubMed ID: 33960000)
1. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
Sugi T; Mita M; Yasu T; Ohara S; Uchida T; Inoue M; Hagihara M
J Clin Pharm Ther; 2021 Dec; 46(6):1792-1795. PubMed ID: 33960000
[TBL] [Abstract][Full Text] [Related]
2. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Yau P; Jimenez-Zepeda VH; Bailey K; Duggan P; Tay J; Bahlis NJ; Neri P; McCulloch S
Leuk Lymphoma; 2019 Dec; 60(13):3199-3203. PubMed ID: 31190585
[TBL] [Abstract][Full Text] [Related]
3. Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
Shamriz O; Parnasa E; Rubin L; Talmon A; Ribak Y; Lebel E; Vainstein V; Aumann S; Saban R; Gatt ME; Tal Y
Eur J Haematol; 2023 Apr; 110(4):407-413. PubMed ID: 36565290
[TBL] [Abstract][Full Text] [Related]
4. Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma.
Sugi T; Nishigami Y; Saigo H; Hanai H; Takabatake K; Mita M; Ohara S; Ide S; Uchida T; Inoue M; Hagihara M
Leuk Lymphoma; 2021 Jun; 62(6):1405-1410. PubMed ID: 33509006
[TBL] [Abstract][Full Text] [Related]
5. Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash.
Sugi T; Mita M; Yasu T; Kubo K; Kushi R; Hanai H; Ohara S; Uchida T; Inoue M; Hagihara M
J Clin Pharm Ther; 2022 Apr; 47(4):477-482. PubMed ID: 34778985
[TBL] [Abstract][Full Text] [Related]
6. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
Dote S; Ito K; Itakura S; Yasu T; Hira D; Noda S; Yamada S; Kobayashi Y; Terada T
Leuk Lymphoma; 2019 Dec; 60(12):2975-2981. PubMed ID: 31046497
[TBL] [Abstract][Full Text] [Related]
7. Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma.
Buonomo M; Kabbur G; El Jurdi N; Giubellino A; Schultz B
Dermatol Online J; 2021 Dec; 27(12):. PubMed ID: 35499443
[TBL] [Abstract][Full Text] [Related]
8. Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Onishi Y; Yokoyama H; Katsuoka Y; Ito T; Kimura T; Yamamoto J; Nakajima S; Sasaki O; Ara T; Minauchi K; Fukuhara O; Kobayashi N; Noji H; Ota S; Harigae H
Ann Hematol; 2020 Oct; 99(10):2351-2356. PubMed ID: 32865607
[TBL] [Abstract][Full Text] [Related]
9. [Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization].
Hagihara M; Ide S; Ohara S; Uchida T; Inoue M; Hua J
Rinsho Ketsueki; 2019; 60(2):137-139. PubMed ID: 30842382
[TBL] [Abstract][Full Text] [Related]
10. Practical Management of Lenalidomide-Related Rash.
Tinsley SM; Kurtin SE; Ridgeway JA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S64-9. PubMed ID: 26297281
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Knauf W; Aldaoud A; Losem C; Mittermueller J; Neise M; Niemeier B; Harde J; Trarbach T; Potthoff K
Leuk Res; 2018 May; 68():90-97. PubMed ID: 29579627
[TBL] [Abstract][Full Text] [Related]
12. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
Front Immunol; 2018; 9():704. PubMed ID: 29706958
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Jakobsen Falk I; Lund J; Gréen H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist UH; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Cancer Chemother Pharmacol; 2018 Jan; 81(1):183-193. PubMed ID: 29177954
[TBL] [Abstract][Full Text] [Related]
14. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study).
Kalff A; Khong T; Mithraprabhu S; Bergin K; Reynolds J; Bowen KM; Thakurta A; Guzman R; Wang M; Couto S; Ren Y; Spencer A
Leuk Lymphoma; 2019 Sep; 60(9):2143-2151. PubMed ID: 31184224
[TBL] [Abstract][Full Text] [Related]
15. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
Hari P; Ung B; Abouzaid S; Agarwal A; Parikh K
Future Oncol; 2019 Dec; 15(35):4045-4056. PubMed ID: 31625415
[No Abstract] [Full Text] [Related]
17. A Case of Lenalidomide-Associated Papulopustular Rash: Beyond the Epidermal Growth Factor Receptor Inhibitor Spectrum.
Fernandez-Nieto D; Ortega-Quijano D; Jimenez-Cauhe J; Saceda-Corralo D; Bea-Ardebol S
Am J Ther; 2020; 27(4):e417-e419. PubMed ID: 32618603
[No Abstract] [Full Text] [Related]
18. Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature.
Ali SB; Lee WI; Horvath N; Le TA; Smith W; Hissaria P
J Allergy Clin Immunol Pract; 2023 May; 11(5):1503-1508. PubMed ID: 36738926
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
20. A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions.
Demir S; Gelincik A; Coskun R; Ozkan G; Demir N; Paksoy N; Beyaz S; Colakoglu B; Kalayoglu-Besisik S; Nalcacı M; Buyukozturk S
Ann Allergy Asthma Immunol; 2019 Oct; 123(4):394-397. PubMed ID: 31400463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
